# Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

> **NCT04550624** · PHASE2 · COMPLETED · sponsor: **Shanghai Jiahui International Hospital** · enrollment: 27 (actual)

## Conditions studied

- Advanced Biliary Tract Carcinoma

## Interventions

- **DRUG:** Pembrolizumab Injection [Keytruda]
- **DRUG:** Lenvatinib Mesylate

## Key facts

- **NCT ID:** NCT04550624
- **Lead sponsor:** Shanghai Jiahui International Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-15
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-12-02
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04550624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04550624, "Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04550624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*